Overview

An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor

Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is an exploratory clinical study of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in patients with advanced malignant tumor.
Phase:
Phase 1
Details
Lead Sponsor:
Dragonboat Biopharmaceutical Company Limited
Collaborator:
West China Hospital
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins